

Index

A

Acetylcholinesterase (AChE) inhibitors, 38, 50, 63, 184, 186, 191
Acquired immunodeficiency syndrome (AIDS), 257–259
Acute akathisia, 90–91
Acute dystonia, 88, 90, 107, 109, 136
AD. *See* Alzheimer's disease (AD)
Adverse drug reactions, 88, 90, 94, 107, 110
Aging, 8, 10, 18, 19, 21, 22, 28, 33, 38, 47, 164, 166, 180, 236
agPPA. *See* Agrammatic variant of PPA (agPPA)
Agrammatic aphasia, 216–220, 223
Agrammatic variant of PPA (agPPA), 215–222, 225, 226
AIDS. *See* Acquired immunodeficiency syndrome (AIDS)
Akathisia, 74, 88–91, 107, 108, 110, 124, 258
Alpha-synuclein (α -syn), 8, 10, 180, 182, 183, 186, 202
ALS. *See* Amyotrophic lateral sclerosis (ALS)
Alzheimer's disease (AD), 5–10, 21, 22, 27, 28, 32, 33, 38, 46, 48, 63, 67, 68, 73–84, 118, 129–137, 142, 143, 157, 159–161, 163–167, 171, 180–183, 186, 189–191, 202, 205, 224–226, 233, 235, 237, 238, 244
 β -Amyloid ($A\beta$), 8–9, 163, 166, 182, 203, 205
Amyloidopathies, 8–9
Amyloid precursor protein (APP), 8, 163, 183
Amyotrophic lateral sclerosis (ALS), 4, 142, 147–148
Antidepressants, 49, 76, 77, 90, 92, 108, 171
Antipsychotics, 67–69, 74, 83, 88, 90, 92–94, 107–110
AOS. *See* Apraxia of speech (AOS)

Apathy, 6, 64, 67, 68, 73–84, 130, 132, 143, 171, 181, 182, 184, 189, 190, 237, 238, 254
ApoE4. *See* Apolipoprotein E ϵ 4 allele (ApoE4)
Apolipoprotein E ϵ 4 allele (ApoE4), 163
APP. *See* Amyloid precursor protein (APP)
Apraxia, 6, 136, 142, 143, 146, 147, 149–150, 188–191, 217, 256
Apraxia of speech (AOS), 149, 214–220, 223–226
Arteriosclerotic parkinsonism, 202
Assessment, 22, 38, 46, 52, 53, 56, 79–81, 93, 94, 120, 123, 125, 130–132, 165, 189, 238–241, 245
Atypical parkinsonism, 62, 187–192

B

Balance, 20–22, 32, 33, 46–54, 56, 172, 214, 218
Behavioral variant frontotemporal dementia (bvFTD), 142–144, 148, 149
BFCRS. *See* Bush-Francis Catatonia Rating Scale (BFCRS)
Binswanger encephalopathy, 202
Buccolingualomasticatory syndrome, 92
Bush-Francis Catatonia Rating Scale (BFCRS), 81
bvFTD. *See* Behavioral variant frontotemporal dementia (bvFTD)

C

Catatonia, 73–84, 88, 90
Catechol-O-methyltransferase (COMT) inhibitors, 64

- CBD. *See* Corticobasal degeneration (CBD)
 CBS. *See* Corticobasal syndrome (CBS)
 Center for Epidemiologic Studies Depression Scale (CES-D), 76
 Cerebrospinal fluid (CSF), 130, 159, 166, 232, 233, 238, 240–245
 Cerebrovascular disease (CVD), 27, 49–52, 55, 200–205, 207, 208, 239
 CES-D. *See* Center for Epidemiologic Studies Depression Scale (CES-D)
 ChEIs. *See* Cholinesterase inhibitors (ChEIs)
 Cholinergic dysfunction, 49, 50
 Cholinesterase inhibitors (ChEIs), 55, 79, 122, 137, 171, 184, 209
 Chorea, 3, 4, 88, 89, 91–93, 109, 254, 255, 258–260, 263–266
 Chromosome 17, 68, 145–147, 225
 CJD. *See* Creutzfeldt–Jakob disease (CJD)
 Clinical Global Impression of Change (CGIC) scale, 83
 Cognitive fluctuations, 158
 Cognitive impairment, 17–38, 46–56, 62, 66, 68, 90, 91, 123, 130, 159–161, 164, 166, 168, 171, 180, 183, 184, 188–190, 192, 204, 207, 237, 238, 241, 245, 254, 257, 261, 262, 266
 Cognitive manifestations, 159, 161
 Columbia University Parkinson's Disease Rating Scale, 124
 C9ORF72, 142–144, 147–148, 150, 226
 Cornell Scale for Depression in Dementia (CSDD), 76
 Corticobasal degeneration (CBD), 3, 5, 8, 9, 68, 187–192, 224, 225
 Corticobasal syndrome (CBS), 7, 62, 63, 66, 69, 136, 137, 142, 143, 145, 149, 188–191, 214–223, 254
 Creutzfeldt–Jakob disease (CJD), 3–5, 11, 133–135, 260
 CSDD. *See* Cornell Scale for Depression in Dementia (CSDD)
 CSF. *See* Cerebrospinal fluid (CSF)
 CVD. *See* Cerebrovascular disease (CVD)
- D**
 Dementia, 1–12, 17–38, 45–56, 61–69, 74, 76–79, 82, 83, 99, 118–120, 122–125, 129–131, 133, 134, 137, 141–150, 157–159, 161, 163–165, 179–192, 199–209, 224, 233–235, 237, 244, 253–266
 Dementia associated with Parkinson's disease, 4, 46–50, 52, 55, 62–64, 68, 118, 119, 122, 157, 160, 161, 163, 164, 166, 167, 180–188, 191
 Dementia with Lewy bodies (DLB), 7, 8, 20, 26, 46–49, 62–64, 68, 69, 118, 119, 122, 133–135, 145, 148, 155–172, 181–184, 186–188, 192, 233
 Depression, 6, 23, 73–84, 132, 137, 148, 162, 165, 171, 181–182, 184, 189, 190, 209, 237, 238, 262
 Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), 74, 75, 81, 82
 DIMDs. *See* Drug-induced movement disorders (DIMDs)
 DIP. *See* Drug-induced parkinsonism (DIP)
 DIPD. *See* Drug-induced parkinsonism and dementia (DIPD)
 DLBD, 8, 133–135, 137
 Drug-induced movement disorders (DIMDs), 87–111, 124
 Drug-induced parkinsonism (DIP), 61, 67–69, 88, 91, 93, 94, 107, 109, 144
 Drug-induced parkinsonism and dementia (DIPD), 63, 67
 Dual energy x-ray absorptiometry (DXA), 56
 DXA. *See* Dual energy x-ray absorptiometry (DXA)
 Dystonia, 4, 5, 11, 62, 88–90, 92, 93, 107–110, 124, 135–137, 146–149, 188, 217, 219, 254, 258–260
- E**
 ECT. *See* Electroconvulsive therapy (ECT)
 EDS. *See* Excessive daytime sleepiness (EDS)
 Electroconvulsive therapy (ECT), 82, 92
 Encephalitis subcorticalis chronica progressive, 201
 ESRS. *See* Extrapyramidal Symptom Rating Scale (ESRS)
 Excessive daytime sleepiness (EDS), 170, 172, 184
 Extrapyramidal Symptom Rating Scale (ESRS), 124
- F**
 Falls, 3, 18–26, 29–33, 38, 45–56, 76, 147–148, 162, 187, 188, 207, 214, 218, 236, 239
 Filament inclusion disorders, 9–10

- Frontotemporal dementia (FTD), 3, 4, 6, 7, 9, 10, 12, 68, 131, 141–150, 157, 182, 188, 224, 233, 260
- Frontotemporal lobe dementia (FTLD), 62, 63, 67–69, 142, 143, 147
- FTD. *See* Frontotemporal dementia (FTD)
- FTDP-17, 8, 9, 145–147, 149, 224, 226
- FTLD. *See* Frontotemporal lobe dementia (FTLD)
- Functional Assessment Staging (FAST) scale, 125
- FUSpathies, 9
- G**
- Gait, 17–38, 46–56, 62, 64, 66, 92, 118, 119, 123–125, 132, 133, 144, 188, 202, 205–207, 214, 219, 236, 237, 239–242
- Gait abnormalities, 27, 38, 53–54, 124
- Gait disorders, 17–38, 48, 132
- Gegenhalten, 81, 137, 217
- Genetics, 130, 147, 148, 150, 163, 183, 225–226
- H**
- Hallucinations, 62–65, 68–69, 83, 91, 144, 147, 159, 161, 165, 171, 181, 184, 189–190, 254, 256
- High-level gait disorders (HLGD), 50
- HIV infection, 254, 257–260
- HLGD. *See* High-level gait disorders (HLGD)
- Huntington's disease, 11, 88, 257
- Hydrocephalus, 5, 61–63, 165–166, 232–235, 239, 243–244, 262
- I**
- ICARS. *See* International Cerebellar Ataxia Rating Scale (ICARS)
- Idiopathic, 7, 61, 62, 67, 68, 88, 90, 91, 110, 157, 159, 163, 171, 200, 203, 233–235, 238
- Infectious dementias, 253–266
- International Cerebellar Ataxia Rating Scale (ICARS), 122
- L**
- LBs. *See* Lewy bodies (LBs)
- Lewy bodies (LBs), 3, 10–11, 20, 46, 48, 134, 145, 157, 162–164, 166–167, 180, 182, 183, 224
- Lewy body disease (LBD), 48, 49, 135, 157, 158, 164, 224
- Lewy body inclusions, 157
- Logopenic variant of PPA (lvPPA), 217–219, 221, 222, 224–226
- Lower-body parkinsonism, 236
- lvPPA. *See* Logopenic variant of PPA (lvPPA)
- M**
- Magnetic gait, 66
- MAP. *See* Microtubule-associated protein (MAP)
- MCI. *See* Mild cognitive impairment (MCI)
- MDS-UPDRS. *See* Movement Disorder Society-sponsored version of the UPDRS (MDS-UPDRS)
- Methylphenidate (MPH), 38, 79
- Microtubule-associated protein (MAP), 9
- Microtubule-associated protein tau (*MAPT*) gene, 9, 142, 145–148, 150, 183, 226
- Mild cognitive impairment (MCI), 18, 21–27, 37, 46, 49, 54–56, 123, 159, 161, 180, 181, 184, 186, 187, 240
- MND. *See* Motor neuron disease (MND)
- Monoamine oxidase B (MAO-B) inhibitors, 64
- Motor, 4–6, 18–21, 23, 27, 33, 38, 50, 52, 53, 55, 63–68, 73–74, 76, 77, 79–82, 89, 93, 107, 108, 118–125, 131–134, 143, 147, 156, 159, 161, 162, 164, 165, 171, 180, 181, 183, 184, 189–192, 200, 201, 214–216, 218–220, 226, 234, 236, 242, 256, 257, 259–260, 263
- Motor manifestations, 74, 159
- Motor neuron disease (MND), 5, 218, 225
- Movement disorders, 2–5, 7, 9–10, 49, 82–84, 87–111, 124, 129–137, 141–150, 158, 218–219, 253–266
- Movement Disorder Society-sponsored version of the UPDRS (MDS-UPDRS), 121, 122
- MPH. *See* Methylphenidate (MPH)
- MSA. *See* Multiple system atrophy (MSA)
- Multiple system atrophy (MSA), 3, 5, 8, 10, 62, 91, 122–125, 136, 163, 167, 187–188, 191–192, 206, 224
- Myoclonus, 62, 89, 91–93, 108, 134, 136, 146–149, 159, 188, 217, 219, 258, 260, 266

N

The National Institute of Mental Health (NIMH), 75, 76
 NBIA. *See* Neurodegeneration with brain iron accumulation (NBIA)
 NC. *See* Neurocysticercosis (NC)
 NCI. *See* Neuronal cytoplasmic inclusions (NCI)
 NCS. *See* Northoff Catatonia Scale (NCS)
 Neurocysticercosis (NC), 261–263, 266
 Neurodegeneration with brain iron accumulation (NBIA), 5, 11
 Neurodegenerative disorders, 1–12, 118, 119, 157, 166, 180, 214
 Neuroferritinopathies, 12
 Neuroleptic malignant syndrome (NMS), 65, 81
 Neuroleptics, 20, 67, 83, 90, 93, 107, 110, 131, 136, 137, 162, 171, 258, 259, 262, 265
 Neuroleptic sensitivity, 158, 162, 171
 Neuronal cytoplasmic inclusions (NCI), 12
 Neuronal intermediate filament inclusion disorders (NIFID), 9–10
 Neuropathology, 2, 5, 6, 9, 12, 131, 182–183, 190–191, 201, 202
 Neuropsychiatric Inventory (NPI), 79, 189, 190
 Neuropsychiatric manifestations, 161–162
 Neuropsychiatric symptoms, 68, 88, 130, 165, 167, 171, 181, 189, 190
 Neurosyphilis, 254–255, 266
 NIFID. *See* Neuronal intermediate filament inclusion disorders (NIFID)
 NIMH. *See* The National Institute of Mental Health (NIMH)
 NMS. *See* Neuroleptic malignant syndrome (NMS)
 NNIPPS-PPS, 124
 Non-Lewy body α -synucleinopathies, 10
 Non-motor manifestations, 159–162
 Normal pressure, 232–233
 Normal-pressure hydrocephalus (NPH), 5, 61–63, 66, 231–245
 Northoff Catatonia Scale (NCS), 81
 NPH. *See* Normal-pressure hydrocephalus (NPH)
 NPI. *See* Neuropsychiatric Inventory (NPI)

P

Palliative Care Outcome Scale-Parkinsonism Plus (POS-PP), 125
 Paratonia, 81, 137

Parkinsonism, 1–12, 48, 49, 61–69, 73–84, 88, 89, 91, 108–110, 117–125, 131–136, 143–150, 158, 159, 163, 167–171, 179–192, 199–209, 214, 222, 224–226, 234, 236, 254–260, 262, 266
 Parkinson's disease (PD), 4, 6–8, 10, 21, 37, 38, 46, 50, 51, 61, 62, 65, 67, 77, 80, 82, 88, 89, 91–94, 118, 120–122, 125, 131, 134, 136, 144, 148, 156–157, 159–161, 163–167, 171, 172, 179–192, 203, 205–207, 209, 233, 236–238, 254, 256, 257
 Parkinson's disease with dementia (PDD), 46, 50, 64, 118, 157, 160, 161, 163, 164, 166, 167, 180–188, 191
 PD. *See* Parkinson's disease (PD)
 PDD. *See* Parkinson's disease with dementia (PDD)
 Pedunclopontine nucleus (PPN), 50, 51, 137, 162
 PEPS. *See* Pyramidal and extrapyramidal scale (PEPS)
 Perry syndrome, 148
 PET. *See* Positron emission tomography (PET)
 Pharmacovigilance, 137
 PIGD. *See* Postural instability gait difficulty (PIGD)
 Pisa syndrome, 136–137
 PNFA. *See* Progressive nonfluent aphasia (PNFA)
 Polyglutamine disorders, 11
 Positron emission tomography (PET), 94, 130, 158, 166, 203
 POS-PP. *See* Palliative Care Outcome Scale-Parkinsonism Plus (POS-PP)
 POS-S. *See* POS-symptoms (POS-S)
 POS-symptoms (POS-S), 125
 Postencephalitic parkinsonism, 254–257, 266
 Postural instability gait difficulty (PIGD), 64, 119, 159, 160, 165
 PPA. *See* Primary progressive aphasia (PPA)
 PPAOS. *See* Primary progressive AOS (PPAOS)
 PPN. *See* Pedunclopontine nucleus (PPN)
 Primary progressive AOS (PPAOS), 149, 213–216, 218–220, 223, 224, 226
 Primary progressive aphasia (PPA), 6, 7, 213–226
 Prion diseases, 11, 261, 266
 Prions, 11, 260–261
 Programmable valve, 243–245
 Progressive nonfluent aphasia (PNFA), 142–144, 149, 188

Progressive supranuclear palsy (PSP), 3, 5, 7–10, 62, 63, 65, 66, 68, 69, 121–125, 142, 143, 145–147, 149, 182–184, 187–192, 206, 224, 233, 259

Progressive supranuclear palsy rating scale (PSPRS), 123

PSP. *See* Progressive supranuclear palsy (PSP)

PSPRS. *See* Progressive supranuclear palsy rating scale (PSPRS)

Psychosis, 64, 69, 73–84, 119, 165, 171, 186, 209, 255, 257, 264

Pyramidal and extrapyramidal scale (PEPS), 123–124

R

Randomized-controlled trials (RCTs), 38, 53, 64, 76, 77, 79, 82, 83, 107, 170, 172, 243

Rapid eye movement (REM), 74, 158, 162

Rating Scale for Gait Evaluation in Cognitive Deterioration (RSGE-CD), 125

Rating scales, 65, 78, 80, 81, 120–125, 144

RCTs. *See* Randomized-controlled trials (RCTs)

REM. *See* Rapid eye movement (REM)

REM sleep behavior disorders (RBD), 158, 162, 170, 172

Restless legs syndrome (RLS), 90

Risk factors, 20, 46–50, 54–56, 67, 90–92, 122, 163, 183, 188–189, 200, 207

RLS. *See* Restless legs syndrome (RLS)

RNA–DNA binding proteins, 9

RSGE-CD. *See* Rating Scale for Gait Evaluation in Cognitive Deterioration (RSGE-CD)

S

SANS. *See* Scale for the Assessment of Negative Symptoms (SANS)

SC. *See* Sydenham's chorea (SC)

SCA. *See* Spinocerebellar ataxias (SCA)

Scale for the Assessment of Negative Symptoms (SANS), 79

Scales for Outcomes in Parkinson's Disease (SCOPA), 125

SCIA. *See* Structured clinical interview for apathy (SCIA)

sCJD. *See* Sporadic Creutzfeldt–Jakob disease (sCJD)

SCOPA. *See* Scales for Outcomes in Parkinson's Disease (SCOPA)

SD. *See* Semantic dementia (SD)

Selective serotonin reuptake inhibitors (SSRIs), 49, 76, 79, 171, 209

Semantic dementia (SD), 6, 142, 143

Semantic variant of PPA (svPPA), 217–219, 221, 222, 224–226

Shunt, 66, 232, 235, 236, 238, 240–245

Silent small vessel disease, 201

Single photon emission computed tomography (SPECT), 94, 158, 166, 203, 236

SPECT. *See* Single photon emission computed tomography (SPECT)

Spinocerebellar ataxias (SCA), 11

Sporadic Creutzfeldt–Jakob disease (sCJD), 157, 159, 260

SSRIs. *See* Selective serotonin reuptake inhibitors (SSRIs)

Structured clinical interview for apathy (SCIA), 78

Subcortical dementia, 6, 66, 190

svPPA. *See* Semantic variant of PPA (svPPA)

Sydenham's chorea (SC), 263–266

Synucleinopathies, 3, 8, 10–11, 162–164, 166, 167, 188, 192, 224

T

Tardive dyskinesia (TD), 88, 92–94, 107, 110

Tardive syndromes, 89, 92–93, 110

Tau, 9, 130–131, 142, 145, 166, 182, 183, 190, 202, 203, 205, 224, 226

Tauopathies, 3, 8, 9, 12, 183, 188, 224, 225

TCAs. *See* Tricyclic antidepressants (TCAs)

TD. *See* Tardive dyskinesia (TD)

TDP-43, 9, 142, 143, 145–148, 224, 225

Treatment, 38, 55, 56, 61–69, 74, 76–77, 79, 80, 82, 83, 90, 92, 93, 108–111, 122–124, 129, 131, 165, 167, 171, 184, 186, 187, 191, 192, 208, 209, 242–244, 255, 257, 259–263, 265

Tremor, 32, 38, 61–64, 66, 68, 83, 88, 89, 91–93, 108–110, 124, 132–134, 144–146, 148, 159, 160, 171, 181, 219, 257–260

Tricyclic antidepressants (TCAs), 76, 108, 170, 171

U

UMSARS. *See* Unified Multiple System Atrophy Rating Scale (UMSARS)

Unified Multiple System Atrophy Rating Scale (UMSARS), 123

Unified Parkinson's disease rating scale (UPDRS), 80, 82, 120–124, 132, 134, 144

UPDRS. *See* Unified Parkinson's disease rating scale (UPDRS)
Urinary incontinence, 66, 162, 172, 207, 236, 240, 241

V

VAD. *See* Vascular dementia (VAD)
Variant Creutzfeldt–Jakob disease (vCJD), 260, 261
Vascular dementia (VAD), 27, 28, 31, 32, 38, 46, 67, 131, 137, 157, 199–209, 233
Vascular parkinsonism (VP), 61, 63, 67, 199–209
VBM. *See* Voxel-based morphometry (VBM)

vCJD. *See* Variant Creutzfeldt–Jakob disease (vCJD)
Ventricle, 201–202, 232, 233, 243
VH. *See* Visual hallucinations (VH)
Visual hallucinations (VH), 158, 161, 171, 181, 184, 256
Voxel-based morphometry (VBM), 147, 219
VP. *See* Vascular parkinsonism (VP)

W

Webster scale, 124
White matter hyperintensities (WMH), 19, 32, 33
WMH. *See* White matter hyperintensities (WMH)